ArticleOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
Implementation of a Nebulized Tranexamic Acid Protocol for Pediatric Post-Tonsillectomy Hemorrhage: A Quality Improvement Initiative.
Article in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Tranexamic Acid Safe and Effective for Treatment of Pediatric Postoperative Tonsillectomy Bleeds?The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe hypothesized that initiation of a standardized nebulized TXA protocol for posttonsillectomy hemorrhage (PTH) would reduce the need for surgical control of bleeding without increasing adverse clinical outcomes.
methodsThis quality improvement project included patients under 18 years of age who presented with PTH. Preintervention data were collected between January 1, 2020, and June 30, 2022. Plan-Do-Study-Act (PDSA) cycle 1, between July 1, 2022, and December 31, 2023, included patients who received nebulized TXA without a standardized protocol, based on emerging evidence supporting its use in PTH. PDSA cycle 2, between January 1, 2024, and July 13, 2025, followed the implementation of a standardized TXA protocol. Data included need for surgical control of bleeding, length of stay, transfusions, readmissions, and TXA-related complications.
resultsA total of 501 patients were included, with a median age of 7.2 years, distributed across the preintervention group (n = 171), PDSA 1 (n = 205), and PDSA 2 (n = 125). The proportion of patients requiring surgical control of bleeding decreased with each intervention (43.9% vs 29.8% vs 15.2%, P < .0001). There were no changes in the length of stay, transfusion rates, readmissions, or TXA-related complications. DISCUSSION: Across 2 PDSA cycles, we achieved a 65.4% reduction in the need for surgical control of bleeding for PTH without an increase in balancing measures, used as surrogates for unintended consequences of the interventions. IMPLICATIONS FOR PRACTICE: Implementation of a nebulized TXA protocol may be a safe and effective management option for PTH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.